Cannabisol, cannabitwinol, cannabizetol: what do these three promising new cannabinoids have in common?

Previously unknown methylene-bridged cannabinoid dimers are now being discovered in cannabis. These unique molecules, formed of two cannabinoid units linked by a methylene bridge, could open the way to novel medical applications thanks to their complex bioactivities.

The rise of dimeric cannabinoids

Traditionally, research has focused on well-known cannabinoids such as Δ9-tetrahydrocannabinol (THC) and the cannabidiol (CBD). While these compounds have well-defined pharmacological profiles, recent studies show that the Cannabis produces a variety a much wider range of bioactive molecules, including cannabinoid dimers, which form when two standard cannabinoids chemically bond.

One of the first methylene-bridged dimers identified was cannabisol, a dimer of Δ9-THC. The researchers described cannabisol as a C-bridged dimeric cannabinoid whose structure has been confirmed by a combination of high-resolution mass spectrometry, nuclear magnetic resonance and gas chromatography.

After cannabisol, scientists isolated cannabitwinol (CBDD), a methylene-bridged dimer of CBD. Cannabitwinol exhibits distinct bioactivity compared to its monomeric counterparts, particularly in the modulation of TRP channels which are involved in the detection of thermal and chemical stimuli. This discovery indicates that dimerization can significantly alter the biological profile of a cannabinoid, creating new new opportunities pharmacological.

Cannabizetol: a promising bioactive metabolite

The latest breakthrough in the cannabinoid research dimers is the identification of the cannabizetol (CBGD). Published in the Journal of Natural Products, the study highlights the remarkable antioxidant properties and anti-inflammatory of cannabizetol, even surpassing those of previously identified dimers such as cannabitwinol.

Researchers tested cannabizetol on 84 inflammatory genes using RT-PCR matrices advances. The compound demonstrated significant inhibition of NF-κB pathway, a molecular switch central to inflammation in several cell types. These findings suggest that cannabizetol may have potential for dermatological applications, positioning it as a notable addition to the growing list of promising cannabinoids.

The study also highlights the wider importance of methylene-bridged dimers.

«Natural dimeric compounds are of considerable importance, as they allow further exploration of chemical space, which could lead to new biological activities beyond those of their respective monomers,» write the authors. The researchers believe that other dimeric cannabinoids, including hybrids composed of different cannabinoid monomers, could exist and are waiting to be discovered.

Expanding the chemical landscape of cannabis

These discoveries are part of a wider effort to mapping the metabolome of Cannabis sativa, which now includes over 100 characterized cannabinoids. Advances in analytical technologies, from high-resolution mass spectrometry to sophisticated NMR techniques, have played a key role in the detection of these complex molecules.

For example, studies carried out in 2025 identified 33 genetic markers influencing the cannabinoid production, This provides the tools to develop plant varieties with customized chemical profiles.

The emergence of dimeric cannabinoids is particularly interesting, since these molecules represent a hitherto unexploited layer of cannabis chemistry. Unlike standard cannabinoids, dimers can present unique binding properties, target different receptors and offer bioactivities not observed in monomeric forms. This opens up prospects not only in pharmacology, but also in dermatology, neuroprotection and inflammation management.